Innovax-ND-IBD
Newcastle disease, infectious bursal disease and Marek's disease vaccine (live recombinant)
Table of contents
Overview
Innovax-ND-IBD is a veterinary vaccine used to protect chickens against Newcastle disease (ND), infectious bursal disease (IBD) and Marek’s disease (MD).
ND is a viral infection of chickens which causes gasping and coughing, nervous signs (drooping wings, twisting of the head and neck, circling and paralysis), swelling of the tissues around the eyes and neck, greenish watery diarrhoea and reduced egg production.
IBD, also known as Gumboro disease, is a viral infection of chickens associated with death at 3-6 weeks of age. It can make birds more prone to other diseases and can interfere with effective vaccination.
MD is a herpesvirus infection of chickens which can cause paralysis of the wings and legs and causes tumours in various organs. Chickens become infected at an early age via inhalation of dander (flakes of skin) containing the virus which can remain infectious for several months after being shed from the body. Birds infected with MD virus can be carriers and shedders of the virus for life.
Innovax-ND-IBD contains a live modified strain of turkey herpesvirus called strain HVP360. The turkey herpesvirus strain HVP360 has been modified so that it will produce proteins from ND virus and IBD virus.
Authorisation details
Product details | |
---|---|
Name |
Innovax-ND-IBD
|
Agency product number |
EMEA/V/C/004422
|
Active substance |
Cell-associated live recombinant turkey herpesvirus (strain HVP360), expressing the fusion protein of ND virus and the VP2 protein of IBD virus
|
International non-proprietary name (INN) or common name |
Newcastle disease, infectious bursal disease and Marek's disease vaccine (live recombinant)
|
Species |
|
Anatomical therapeutic chemical veterinary (ATCvet) codes |
QI01AD16
|
Publication details | |
---|---|
Marketing-authorisation holder |
Intervet International B.V.
|
Revision |
5
|
Date of issue of marketing authorisation valid throughout the European Union |
22/08/2017
|
Contact address |
Wim de Körverstraat 35 |
Product information
09/09/2021 Innovax-ND-IBD - EMEA/V/C/004422 - WS2102/G
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Therapeutic indication
For active immunisation of one-day-old chicks or 18-19-day-old embryonated chicken eggs:
- to reduce mortality and clinical signs caused by Newcastle disease (ND) virus,
- to prevent mortality and to reduce clinical signs and lesions caused by infectious bursal disease (IBD) virus,
- to reduce mortality, clinical signs and lesions caused by Marek’s disease (MD) virus.